Versant Venture Management’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-506,821
| Closed | -$2.3M | – | 8 |
|
|
2025
Q3 | $2.3M | Hold |
506,821
| – | – | 1.08% | 9 |
|
|
2025
Q2 | $1.09M | Hold |
506,821
| – | – | 1.33% | 8 |
|
|
2025
Q1 | $2.21M | Hold |
506,821
| – | – | 3.68% | 7 |
|
|
2024
Q4 | $2.37M | Hold |
506,821
| – | – | 2.73% | 7 |
|
|
2024
Q3 | $3.56M | Hold |
506,821
| – | – | 5.6% | 5 |
|
|
2024
Q2 | $3.48M | Sell |
506,821
-1
| -0% | -$9 | 4.5% | 5 |
|
|
2024
Q1 | $7.17M | Sell |
506,822
-1
| -0% | -$15 | 6.95% | 5 |
|
|
2023
Q4 | $3.82M | Hold |
506,823
| – | – | 0.98% | 6 |
|
|
2023
Q3 | $7.6M | Hold |
506,823
| – | – | 4.04% | 4 |
|
|
2023
Q2 | $8.06M | Hold |
506,823
| – | – | 9.56% | 3 |
|
|
2023
Q1 | $3.64M | Hold |
506,823
| – | – | 7.58% | 5 |
|
|
2022
Q4 | $2.94M | Hold |
506,823
| – | – | 6.08% | 5 |
|
|
2022
Q3 | $4.82M | Hold |
506,823
| – | – | 8.21% | 4 |
|
|
2022
Q2 | $6.08M | Hold |
506,823
| – | – | 9.32% | 4 |
|
|
2022
Q1 | $6.64M | Hold |
506,823
| – | – | 6.63% | 7 |
|
|
2021
Q4 | $8.92M | Hold |
506,823
| – | – | 4.77% | 7 |
|
|
2021
Q3 | $11M | Hold |
506,823
| – | – | 4.55% | 7 |
|
|
2021
Q2 | $17.7M | Hold |
506,823
| – | – | 5.88% | 5 |
|
|
2021
Q1 | $50M | Buy |
506,823
+6,434
| +1% | +$773K | 9.74% | 4 |
|
|
2020
Q4 | $54.2M | Sell |
500,389
-200,000
| -29% | -$24.7M | 5.63% | 4 |
|
|
2020
Q3 | $72.1M | Hold |
700,389
| – | – | 13.2% | 2 |
|
|
2020
Q2 | $146M | Sell |
700,389
-6,434
| -0.9% | -$1.14M | 21.01% | 2 |
|
|
2020
Q1 | $69.1M | Buy |
+706,823
| New | +$82.4M | 18.94% | 2 |
|
Versant Venture Management's ADVM Position: Q4 2025 in Review
Versant Venture Management sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 506,821 shares — an estimated $2.3M sold.
Versant Venture Management first reported a position in ADVM in Q1 2020 and held it in 23 quarters. The position peaked at $146M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Versant Venture Management reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Versant Venture Management sold 506,821 Adverum Biotechnologies shares in Q4 2025, an estimated $2.3M.
- Versant Venture Management first reported a position in Adverum Biotechnologies in Q1 2020 and held it in 23 quarters.
- Versant Venture Management's Adverum Biotechnologies position peaked at $146M in Q2 2020.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Versant Venture Management's 13F filing for Q4 2025, filed 12 Feb 2026.